Cellid, Co., Ltd.

KOSDAQ:A299660 Stock Report

Market Cap: ₩106.1b

Cellid Balance Sheet Health

Financial Health criteria checks 2/6

Cellid has a total shareholder equity of ₩54.7B and total debt of ₩10.4B, which brings its debt-to-equity ratio to 19.1%. Its total assets and total liabilities are ₩75.1B and ₩20.4B respectively.

Key information

19.1%

Debt to equity ratio

₩10.44b

Debt

Interest coverage ration/a
Cash₩14.11b
Equity₩54.74b
Total liabilities₩20.37b
Total assets₩75.11b

Recent financial health updates

Recent updates

Is Cellid (KOSDAQ:299660) Weighed On By Its Debt Load?

Dec 10
Is Cellid (KOSDAQ:299660) Weighed On By Its Debt Load?

Is Cellid (KOSDAQ:299660) Using Debt In A Risky Way?

Feb 28
Is Cellid (KOSDAQ:299660) Using Debt In A Risky Way?

Is Cellid (KOSDAQ:299660) In A Good Position To Invest In Growth?

Mar 04
Is Cellid (KOSDAQ:299660) In A Good Position To Invest In Growth?

Cellid (KOSDAQ:299660) Is In A Good Position To Deliver On Growth Plans

Nov 19
Cellid (KOSDAQ:299660) Is In A Good Position To Deliver On Growth Plans

Financial Position Analysis

Short Term Liabilities: A299660's short term assets (₩16.5B) exceed its short term liabilities (₩3.2B).

Long Term Liabilities: A299660's short term assets (₩16.5B) do not cover its long term liabilities (₩17.2B).


Debt to Equity History and Analysis

Debt Level: A299660 has more cash than its total debt.

Reducing Debt: A299660's debt to equity ratio has increased from 2.6% to 19.1% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: A299660 has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: A299660 has less than a year of cash runway if free cash flow continues to reduce at historical rates of 19.2% each year


Discover healthy companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 00:36
End of Day Share Price 2024/12/26 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Cellid, Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution